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ABSTRACT: Although uncommon, cancer of an unknown primary (CUP)
metastatic to cervical lymph nodes poses a range of dilemmas relating
to optimal treatment. The ideal resolution would be a properly designed
prospective randomized trial, but it is unlikely that this will ever be
conducted in this group of patients. Accordingly, knowledge gained from
retrospective studies and experience from treating patients with known
head and neck primary tumors form the basis of therapeutic strategies
in CUP. This review provides a critical appraisal of various treatment
approaches described in the literature. Emerging treatment options for
CUP with metastases to cervical lymph nodes are discussed in view of
recent innovations in the field of head and neck oncology and suitable
therapeutic strategies for particular clinical scenarios are presented. For
pN1 or cN1 disease without extracapsular extension (ECE), selective
neck dissection or radiotherapy offer high rates of regional control. For
more advanced neck disease, intensive combined treatment is required,
either a combination of neck dissection and radiotherapy, or initial
(chemo)radiotherapy followed by neck dissection if a complete response
is not recorded on imaging. Each of these approaches seems to be
equally effective. Use of extensive bilateral neck/mucosal irradiation
must be weighed against toxicity, availability of close follow-up with
elective neck imaging and guided fine-needle aspiration biopsy (FNAB)
when appropriate, the human papillomavirus (HPV) status of the tumor,
and particularly against the distribution pattern (oropharynx in the
majority of cases) and the emergence rate of hidden primary lesions
(<10% after comprehensive workup). The addition of systemic agents is
expected to yield similar improvement in outcome as has been observed
for known head and neck primary tumors. VC 2012 Wiley Periodicals,
Inc. Head Neck 35: 286–293, 2013
KEY WORDS: cervical lymph node metastases, unknown primary
tumor, squamous cell carcinoma, (chemo)radiotherapy, neck
dissection
Cancer of unknown primary (CUP) metastatic to cervical
lymph nodes is uncommon. After a comprehensive diag-
nostic workup, the expected incidence of CUP in the
head and neck is around 3% of patients with cervical
lymph node malignancy, with squamous cell carcinoma
(SCC) accounting for up to two thirds of cases.1–4 The
diagnostic approaches for patients with cervical lymph
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node metastasis from an occult primary tumor were
reviewed recently and an optimal diagnostic workup was
proposed.5
Historically, treatment of CUP metastatic to cervical
lymph nodes was aimed at eradicating existing nodal dis-
ease as well as the hidden focus of the potential index
cancer that was not discovered during the diagnostic
workup. In this context, the choice of a particular treat-
ment approach should be based on the accuracy of the
diagnostic workup for assessment of: (1) extent of disease
in the neck; and (2) probability that a particular part of
the upper aerodigestive tract is not the origin of the occult
primary. However, according to a comprehensive litera-
ture review of studies published before 2000 by Nieder et
al,6 the risk of nodal recurrence and distant metastases is
at least twice higher than the subsequent appearance of a
mucosal primary tumor. This should also be taken into
account when planning therapy.
As diagnostic facilities and levels of expertise vary con-
siderably across hospitals and countries, several treatment
approaches have been implemented. Furthermore, the effi-
cacy of an individual treatment approach should be
assessed separately for neck control and for mucosal con-
trol and weighed against treatment-related morbidity as a
consequence of a particular therapy. The issue of optimal
therapy for CUP with cervical lymph node metastases is
further complicated by its uncommon occurrence and the
variable rate of subsequent evolution of a mucosal pri-
mary across international centers; these factors have pre-
cluded the execution of properly designed multicenter
randomized trials. The questions asked most frequently in
the relevant literature are as follows: when is single-mo-
dality therapy sufficient; what is the optimal extent of
neck surgery or radiation fields; what is the treatment ef-
ficacy of radiotherapy (RT) versus the combination of
surgery and irradiation, particularly in view of human
papillomavirus (HPV) status of biopsied neck nodes; is
there a place for systemic therapy; and what is the role
for intensity-modulated radiation therapy (IMRT)?
For cervical lymph node metastases of tissue types
other than SCC, the treatment recommendations follow
those for cases with a known primary tumor of a pertinent
histology. The following discussion refers to SCC meta-
static to cervical lymph node from an unknown primary.
EARLY-STAGE NECK DISEASE
In low-volume neck disease, pN1 and early pN2a cases
without extracapsular extension (ECE) on histopathologi-
cal examination, several studies have reported excellent
regional control with either surgery or RT alone. When-
ever surgery is an option, the surgeon must include the
previous scar of open biopsies, dissect, and carefully
include all the area of the previous operation. Although
these studies were small and retrospective, clearance of
the appropriate cervical lymph node levels with either of
these 2 modalities seems adequate. Colletier et al7 found
no neck recurrence in a group of 16 patients with cN1
disease and no ECE, in whom an excisional biopsy pre-
ceded RT. Similarly, Aslani et al8 reported no failure in
the neck in 12 patients who had fine-needle aspiration bi-
opsy (FNAB) or excisional biopsy followed by RT alone.
After a standard radical neck dissection or some of its
modifications, Coster et al9 reported recurrence in the dis-
sected necks in 2 of 13 patients with pN1 disease, both of
whom had ECE. In the series of Miller et al,10 no neck
recurrence was observed in 6 of 7 patients with pN1 dis-
ease and no ECE, treated solely with a selective neck dis-
section; the 1 patient who developed neck recurrence had
ECE. According to Patel et al,11 none of the 4 patients
with pN1 disease without ECE treated by single modality
therapy experienced neck recurrence, whereas Iganej et
al12 reported ultimate tumor control above the clavicles in
81% (13 of 16) of surgically treated patients with pN1/
pN2a disease without ECE and in 89% (8 of 9) treated
with combined modality approaches.
Based on these results derived from small numbers of
patients, it is clear that the enrollment of candidates for
single-modality therapy should be selective. However,
simple excision of an enlarged lymph node even in
patients with a single metastatic lymph node without ECE
is inadequate. It must be followed by clearance of further
neck levels as appropriate or RT of the involved neck.
The latter may have the advantage that, depending on the
radiation volumes, an occult primary tumor located later-
ally in the oropharynx may also receive a sufficiently
high dose to be eliminated. However, if a thorough exam-
ination and appropriate imaging and biopsy/tonsillectomy
looking for a primary tumor are all negative, then the
chance of a primary tumor becoming evident is low, mak-
ing neck dissection a highly effective and cost-effective
form of treatment.
As in the case of N1 neck without ECE that occurs in
the context of the known primary, single modality treat-
ment may suffice and give good control rates. Although
this practice is not backed by high level evidence, very
few centers offer combined modality therapy in this sce-
nario.13 However, only surgery reliably allows the diag-
nosis of ECE. In the case of ECE, postoperative RT, usu-
ally with concomitant chemotherapy, is mandatory in
order to increase local control rates. Nevertheless, it has
been shown that postoperative RT does not increase
locoregional control or survival in patients with com-
pletely resected head and neck SCC with pN1 or pN2
without ECE,14,15 which in turn causes additional morbid-
ity (eg., xerostomia). Conversely, a selective neck dissec-
tion has a very low rate of postoperative complications
and is less expensive than RT.
ADVANCED-STAGE NECK DISEASE AND
MUCOSAL PRIMARY
Single-modality therapy or combined treatment
approach?
For patients with advanced neck disease, combined-mo-
dality therapy is more strongly indicated, although there
are exceptions. For example, Grau et al3 reported a 5-year
neck control of 50%, an overall survival rate of 37% and
a crude emergence rate of head and neck mucosal pri-
mary tumors of 12% in a series of 224 patients treated
only with RT during the period 1975 to 1995. The results
of 2 recent but smaller series demonstrated more encour-
aging figures, most probably due to improvements in
diagnostics and RT techniques, with 5-year neck control
rates of 76.3% and 65.6%; an overall survival rate of
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77.8% and 68.5%; and crude mucosal primary emergence
rates of 7.5% and 16.7%; 40 patients from 1987 to 20028;
and 60 patients from 1989 to 2003.16 In none3,8 or in
only a negligible proportion16 of patients from 3 series,
was chemotherapy added to RT; and in the majority of
cases, both sides of the neck3,8,16 and putative mucosal
primary sites were also irradiated.3,16 However, according
to literature for the period from 1990 to 2003, as summar-
ized by Jereczek–Fossa et al,17 nodal relapse rates
between 0% and 20% and an overall survival at 5 years
between 22% and 67% can be expected with a more in-
tensive combination of comprehensive neck dissection
and RT (involved field RT or bilateral neck/mucosal RT).
Figures from more recent series also show some improve-
ment, ranging from 67.3% to 93% for neck control and
from 40.9% to 78.9% for overall survival at 5 years.8,18–20
When combined therapy was directly compared to RT
alone (111 vs 70 patients), Wallace et al20 reported signifi-
cantly better 5-year neck control rates in patients who
underwent neck dissection: pre-RT neck dissection, 93%;
post-RT neck dissection, 82%; and no neck dissection,
73%. In a smaller group of patients (surgery and RT, 21, vs
RT alone, 40 patients), no advantage for a combination of
neck surgery and postoperative RT was observed by Aslani
et al.8
It is obvious that aggressive combined therapy is
needed for advanced neck disease. However, based on
existing evidence, it is not apparent what the optimal
therapy is: surgery with postoperative RT or initial (che-
mo)radiotherapy followed by neck dissection only in
those patients who do not achieve a complete clinical or
metabolic (positron-emission tomography [PET]) response
to irradiation.
Appearance of the Primary Tumor
The mucosal primary emergence rates are comparable
when studies are analyzed according to the extent of neck
irradiation,17 with up to 12% (in the series of Reddy and
Marks,21 this figure was 44% but only 16 patients were
studied) for ipsilateral versus 2% to 10% for bilateral mu-
cosal irradiation.17 These results are in line with those
presented by Nieder et al6 (8% after unilateral RT and
9.5% after comprehensive RT). A selective approach
regarding the extent of mucosal irradiation was described
by Wallace et al.20 As the majority of unknown primaries
are most likely to occur in the tonsillar area and base of
tongue, only the oropharynx and nasopharynx were encom-
passed in their RT portals; the larynx and hypopharynx
were only included for patients with level III metastases.
Using this criterion, the overall mucosal control rate at 5
years was 92% for the whole group of patients and was
100% for the 28 patients treated with mucosal portals lim-
ited to the nasopharynx and oropharynx. Sites of mucosal
failure were nasopharynx (1 patient), oral cavity (9
patients), and supraglottic larynx (3 patients).20
The emergence rates of mucosal primary tumors after
unilateral neck irradiation are similar to the risk of occur-
rence of metachronous second primary tumors in patients
cured of a known head and neck SCC primary.22 In view
of these data, and their own experience, Sinnathamby et
al23 concluded that most emerging primaries are new
lesions that are unrelated to the index cancer and that the
risk of missing a curable occult primary after a thorough
initial workup is too small to justify the morbidity of
elective irradiation of potential primary sites. In fact, sur-
vival rates are not related to the appearance of the pri-
mary tumor.24 An additional consideration is the potential
complexity of adding re-irradiation as a treatment modal-
ity for the primary site if and when a primary cancer
emerges.
Should Irradiation be Unilateral or Bilateral?
The majority of single-institution retrospective studies
comparing the involved field and elective neck irradiation
did not show any advantage for more extensive
RT,3,16,25,26 although the opposite has also been
reported.21 Literature reviews6,17 suggest improved re-
gional control after nodal resection and bilateral neck
irradiation over ipsilateral neck RT. Consequently, no
firm conclusions can be drawn on this issue. The results
from different studies might also be biased by inclusion
of patients with more advanced/inoperable neck disease
or those in poor general condition into the involved neck
RT group. In clinical practice, candidates for bilateral
neck RT are patients with suspected primary tumors
located close to the midline (ie, base of tongue in HPV-
positive cases after tonsillectomy not disclosing the pri-
mary; nasopharynx in Epstein–Barr virus–positive cases,
and/or suggestive imaging studies but negative biopsy) or
those with extensive nodal disease putting the contralat-
eral neck at increased risk for occult nodal metastases, or
with bilateral nodes. However, any putative advantage of
bilateral RT, particularly when potential sites of the
occult mucosal primary are also irradiated, must be
weighed against close observation during follow-up, with
elective ultrasound and guided FNAB, the morbidity
induced and the limitations of salvage surgery with or
without postoperative curative re-irradiation in the event
of a subsequently manifesting primary tumor or second
primary.
Intensity-Modulated Radiotherapy
Three-dimensional (3D) conformal RT and IMRT (vs
2D-RT), have been found to be a strong independent
prognostic factors for locoregional control and survival in
a recent study.25 The introduction of IMRT during the
last 15 years seemingly abolishes many of the dilemmas
related to irradiation in an unknown primary setting.
However, one must be aware that even with IMRT the
acute and late toxicity of extensive elective irradiation of
potential primary sites and both sides of the neck is sig-
nificantly more pronounced than when RT is limited to
the involved neck. Furthermore, when only the involved
neck is irradiated, IMRT offers no real advantage over
3D conformal RT.
As summarized in Table 1, after a relatively short fol-
low-up time of a median of 2 years in the majority of
studies, an average crude mucosal and neck failure rate of
<5% and 10% (range, 0% to 14.3%), respectively, and
overall survival at 2 years of well above 70% (range,
74.2% to 92%) can be expected after IMRT.27–32 In 2
studies comparing conventional 3-field RT and IMRT,
there were no discernable differences in any relevant
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efficacy endpoints between the 2 irradiation techni-
ques.28,32 Importantly, in both studies, an improved thera-
peutic ratio was found with IMRT when compared to
conventional irradiation, particularly when a dose to the
contralateral (spared) parotid gland and the ipsilateral
inner and middle ear structures was considered.32 For
patients treated by conventional RT and IMRT, the inci-
dence of severe late xerostomia (complete dryness of
mouth) of 58% versus 11%, grade 3þ esophageal toxicity
(liquid diet only) of 42% versus 17%, gastroscopy tube-
dependence at 6 months after treatment of 42% versus
11% (after 1 year 33% vs 0%), and overall grade 3þ late
toxicity of 63% versus 29%, respectively, were reported
by Chen et al.32 Also, in a comparative study by Madani
et al,28 no difference in grade 3 acute mucosal toxicity
was observed between both RT techniques, whereas grade
3 xerostomia (53.4% vs 11.8%), dysphagia (26.7% vs
0%), and skin fibrosis (26.7% vs 0%) at 6 months of fol-
low-up were significantly more common in the historical
group than in the IMRT group. These observations are in
line with the results of a prospective although non-
randomized study conducted in patients with known pri-
mary tumors: patient-rated xerostomia and sticky saliva
were significantly lower among patients treated with
IMRT compared to a historical control group, as were
several other head and neck symptoms. Moreover, the dif-
ferences in patient-rated head and neck symptoms also
translated into higher scores in health-related quality of
life in favor of those treated with IMRT.33
Neck surgery
The decision regarding the type of neck dissection
should be individualized and based on the extent of nodal
disease. Selective neck dissection is usually preferred as
all 5 levels of the neck are rarely at risk: there is no pri-
mary SCC in the head and neck region simultaneously
exposing the sublevels IA/IB and VB at sufficiently high
risk. Furthermore, when there is extensive involvement
along the jugular chain, which is usually the case in an
unknown primary setting, the dissection of sublevel IA
may be omitted.34,35 Therefore, classical radical neck dis-
section is rarely indicated as is—for the same reasons—
comprehensive (levels I–V) neck dissection.
Systemic therapy
Experience with systemic therapy in patients with a
CUP metastatic to cervical lymph nodes is limited. Gen-
erally, there are 2 clinical scenarios in which systemic
drugs might be recommended: the intensification of
(loco)regional treatment, for the purpose of improving
neck control, or to palliate the symptoms of regionally
advanced disease or systemic metastases.
Chemotherapy has been used since the 1980s and first
adapted to unknown primary disease by de Braud et al36
who treated 16 patients with a combination of RT and
chemotherapy. Although 12 of 16 patients had N3 dis-
ease, the complete response rate was 81% and 11 patients
showed no evidence of disease after a median survival
time of 37þ months. In the second group, 28% of the 25
patients treated with surgery and/or RT (9 of 25 with N3
disease) were free of disease after a median follow-up of
24 months. The heterogeneity of the chemotherapy regi-
mens and schedules used, the small sample size and/or
the lack of a control group in de Braud’s and several
other series preclude any relevant final con-
clusions.16,27,30,31,36–39 Recently, Beldı̀ et al19 and Ligey
et al25 reported no advantage in supplementing locore-
gional treatment with chemotherapy: 18% and 45% of
patients from these 2 series, respectively, were treated
with a variety of platinum-based regimens.
The only studies primarily focused on chemotherapy in
an unknown primary setting were those of Shehadeh et
al40 and Chen et al.41 In the first study, 37 patients (with
N2b–N3 disease in 71% of cases) were treated with neck
dissection, bilateral neck/mucosal sites RT, and 3 cycles
of concurrent cisplatin (100 mg/m2 every 3 weeks). The
neck control and distant failure rates were 95% and 11%,
respectively, and 89% of patients were alive after a me-
dian follow-up time of 42 months for survivors. Both
patients with recurrence had N3 disease with ECE and
died as a result of their disease in less than 1 year.40
Recently, Chen et al41 reported on 60 patients, of whom
the majority (75%) were initially operated on and all
patients had bilateral neck/mucosal axis RT (IMRT in
58%). Concurrent cisplatin was administered in 53% of
patients, mainly with a dose of 100 mg/m2 every 3 weeks
and, in selected cases, weekly cisplatin with a dose of 50
mg/m2 was delivered for a median of 4 cycles (range, 3–6
cycles). At 2 years, no advantage of treatment intensifica-
tion was noted with regard to locoregional control, progres-
sion-free or overall survival, and no subset of patients who
would benefit from chemoradiotherapy could be identified.
A significant increase in grade 3þ acute (59% vs 25%)
and late (47% vs 14%) toxicity was associated with con-
current cisplatin. The authors concluded that although
selection bias cannot be excluded, prospective data are
needed to further address this question.41
With improved neck control and the diminished inci-
dence of a subsequent mucosal primary, the problem of
systemic dissemination as a crucial factor that determines
the survival outcome becomes more prominent. The inci-
dence of distant metastases ranges between 11% and 38%
and correlates with advanced N-staging and ECE.6,17 No
study specifically addresses this issue. However, R€odel et
al18 found that in patients with advanced nodal disease
(N2b–N3) the incidence of distant metastases diagnosed
on follow-up was lower when postoperative RT was com-
bined with cisplatin-based chemotherapy (36% vs 59%).
This resulted in a trend of improved overall survival in
the latter group (p ¼ .10). There was no beneficial effect
on neck control observed by adding chemotherapy.18
What can we learn from patients with head and
neck cancer with known primary tumors?
Due to the low incidence of the disease, the studies deal-
ing with CUP metastatic to the cervical lymph nodes usually
cover long time periods which limits their current applicabil-
ity. So, the experiences collected through the management
of neck disease in patients with known primary tumors could
be instructive.
STROJAN ET AL.
290 HEAD & NECK—DOI 10.1002/HED FEBRUARY 2013
Systemic therapy
In clinical practice, the application of chemotherapy in
patients with CUPs most often reflects its use with known
primary tumors. Concurrent application of chemotherapy
and RT can be justified with the highest level of scientific
evidence42 compared to mainly negative conclusions
regarding chemoradiation from small and retrospective
CUP series. Accordingly, ECE and residual disease after
neck surgery are usual indications for combining plati-
num-based chemotherapy with RT in postoperative set-
ting,43 whereas in the presence of unresectable or high
volume (N2–N3) nodal metastases, the efficacy of con-
current chemoradiation as an initial therapy has also been
demonstrated.44,45
Given the relatively high incidence of distant metastases
after advanced neck disease in known and unknown pri-
mary tumor settings an effective systemic therapy is
urgently needed. Encouraging results are emanating from
studies using induction chemotherapy, showing the reduc-
tion in distant metastasis rates for approximately 50% com-
pared to concurrent chemoradiation series (from around
20% to around 10%). Thus, induction chemotherapy is
another promising area for clinical research that is highly
relevant also for patients with CUPs with advanced neck
disease.46
Human papillomavirus
The HPV status of the tumor can be used as a marker
of intrinsic sensitivity to irradiation. Several retrospective
studies47,48 and a prospective analysis of data from a clin-
ical trial49 confirmed that HPV-positivity confers a 60%
to 80% reduction in risk of death from cancer relative to
similarly treated HPV-negative tumors. Recently, Ang et
al50 retrospectively analyzed the association between tu-
mor HPV status and survival among stage III and IV oro-
pharyngeal SCC treated in the Radiation Therapy Oncol-
ogy Group 0129 trial, sufficiently powered to account for
potentially confounding factors, including smoking status
of the patients. Using recursive-partitioning analysis, tu-
mor HPV status was identified as a major determinant of
overall survival, followed by the number of pack-years of
tobacco smoking (10 vs >10) and then N classification
stage of the disease (N0–N2a vs N2b–N3) for HPV-posi-
tive tumors, or T classification of primary tumor (T2–T3
vs T4) for HPV-negative tumors. Accordingly, patients
were classified into 3 prognostic categories with respect
to the risk of death; patients with HPV-positive tumors
were classified into the low-risk group with the exception
of smokers with N2b-N3 neck disease who were consid-
ered to be at intermediate risk.50
In many centers, HPV positivity, particularly in non-
smokers, is nowadays considered a good indication for
irradiation alone or in combination with concurrent chem-
otherapy. Surgery is then reserved only for those patients
not achieving a complete clinical or metabolic response
on posttreatment PET scanning.51 Additional arguments
for selecting RT over surgery in patients with CUPs with
early-stage as well as advanced-stage HPV-positive neck
disease include the relatively lower morbidity as well as
the reduced risk of smoking-related metachronous pri-
mary tumors when only the ipsilateral tonsil and base of
tongue are encompassed by the prophylactic RT. In view
of significantly improved survival results in HPV-positive
patients and substantial toxicity associated with combined
modality therapy, questions emerge as to whether aggres-
sive concurrent chemotherapy schedules can be replaced
with less intensive regimens (eg, low-dose weekly plati-
num) or epidermal growth factor receptor inhibitor or
whether RT alone or even with a modest dose reduction
would be equally effective.52
HPV status is also a favorable prognostic sign for
patients treated primarily with surgery53 and it remains to
be seen through the results of prospective randomized tri-
als whether surgery alone or less intensive nonsurgical
treatment for HPV-positive lymph nodes is effective
enough to be recommended for routine use. Of note,
proper evaluation of functional outcomes and quality of
life should be an integral part of such trials.
CONCLUSIONS
When no primary tumor has been detected after meticu-
lous examination and investigations, the treatment
approach should be individualized and must be adapted to
the pertinent clinical scenario. The few principles and rec-
ommendations that have been gained through retrospec-
tive data analyses and should be considered when plan-
ning a treatment strategy include the following. First,
only patients whose neck disease is controlled benefit
from sterilization of an occult primary tumor.
Second, the emergence rate of occult primary lesions in
patients with CUPs is comparable to the risk of develop-
ing metachronous second primary tumors seen in patients
cured of known primary head and neck SCC.
Third, after a complete diagnostic workup, including
immunostaining, MRI or CT and/or fluorodeoxyglucose-
PET, the risk of missing an occult primary tumor is small
and must be weighed against the morbidity associated
with treatment of suspected primary tumor sites.
Fourth, all 5 neck levels are rarely at risk and, there-
fore, selective neck dissections are preferred over more
extensive comprehensive or radical neck dissections in
the majority of patients.
Fifth, modern RT techniques, particularly IMRT, ensure
an improved therapeutic ratio over conventional 2D RT
when elective irradiation is intended, although they are
not without long-term toxic side-effects.
Sixth. at present, there is no convincing evidence that
the addition of systemic agents to irradiation improves
treatment efficacy in CUP. However, it may be likely that
it will give similar improvements in outcome as have
been seen in known primary tumors of the head and
neck.
Seventh, HPV-positive tumors seem more sensitive to
irradiation than HPV-negative tumors.
Recommendations for early-stage and advanced neck
disease are as follows: (1) pN1 or cN1 disease, without
ECE found on histopathological or radiological studies:
single-modality therapy is indicated (ie, selective neck
dissection or involved field RT alone); (2) N1/ECE-posi-
tive, N2-N3 disease: a combined approach is justified.
Both established therapies seem equally effective (ie,
combination of neck dissection with postoperative RT
and initial chemoradiation with surgery planned only for
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those patients not achieving a clinical or metabolic com-
plete response on posttreatment imaging). Whether less
intensive or even single modality therapy could be
adequate in patients who are HPV-positive, particularly
nonsmokers, has yet to be determined. In view of the dis-
tribution pattern (almost 90% of primaries are located in
the oropharynx) and the low emergence rate of hidden
primary lesions which is comparable to the incidence of
metachronous primaries in patients cured of known index
cancer (<10% after comprehensive initial diagnostic
assessment and ipsilateral neck irradiation), extensive
bilateral/mucosal RT seems not to be indicated for all
patients, particularly if close follow-up is provided with
elective neck imaging and guided FNAB when appropri-
ate and if HPV-positive status is determined. At present,
it is unreasonable to suggest that a radical neck dissec-
tion should be performed in all patients with N2 or N3
neck disease.
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